Skip to content
Cholangiocarcinoma Australia
  • Get Started
  • Give
  • Fundraise
    • Cholangio Challengers
      • Cholangio Challengers For Supporters
      • Cholangio Challengers For Patients
    • Light Australia Green
  • About Us
    • How We Win | A Cholangiocarcinoma Survival System
    • How We Began
    • Contact us
    • Our Team
    • Our Board
  • Patient Portal
    • Histotripsy
    • Articles
    • Order Patient Navigator Journal
    • Newly Diagnosed Patients
    • About CCA
      • Risk factors
      • Symptoms
      • Key Statistics
    • Meetings
    • Newsletter
    • Endorse A Professional
    • Staging and Grading
    • Biomarkers Matter
    • Treatment Options
    • Find a Specialist
    • Second Opinion
    • Find a Mentor
  • Trials
    • Clinical Trials
    • Clinical Trials Submission Portal
  • Clinicians Portal
  • Get Involved
  • Events
    • Calendar
Latest News:
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Brenda’s Testimonial
James Hastings Testimonial
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
Steven West: Cholangio Survivor
Cholangiocarcinoma Australia
  • Get Started
  • Give
  • Fundraise
    • Cholangio Challengers
      • Cholangio Challengers For Supporters
      • Cholangio Challengers For Patients
    • Light Australia Green
  • About Us
    • How We Win | A Cholangiocarcinoma Survival System
    • How We Began
    • Contact us
    • Our Team
    • Our Board
  • Patient Portal
    • Histotripsy
    • Articles
    • Order Patient Navigator Journal
    • Newly Diagnosed Patients
    • About CCA
      • Risk factors
      • Symptoms
      • Key Statistics
    • Meetings
    • Newsletter
    • Endorse A Professional
    • Staging and Grading
    • Biomarkers Matter
    • Treatment Options
    • Find a Specialist
    • Second Opinion
    • Find a Mentor
  • Trials
    • Clinical Trials
    • Clinical Trials Submission Portal
  • Clinicians Portal
  • Get Involved
  • Events
    • Calendar
Latest:
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Brenda’s Testimonial
James Hastings Testimonial
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
Steven West: Cholangio Survivor
Patients
Donate
Clinicians
Cholangiocarcinoma Trial decision making – Navigating the Clinical Trials Maze

Cholangiocarcinoma Trial decision making, In collaboration with the doctors of UCSF Medical Center…

Search more Video content on TAGS

Tags

ARID1A Australia BAP1 Bile Gone Bad BRCA1/2 Car-T Cells Checkpoint Pathway Chemotherapy Clinical Trial dmmr durvalumab EGFR FGFR2 Gem/Cis Gem/Cis/Durva Graeme Holmes How iCCA IDH1 immunotherapy Intrahepatic Keytruda MSI-H Mutations olaparib Oncologists patient Patient Success Patient Survivor PD-1 Checkpoint inhibitors PD-L1 research Steve Holmes Surgery Testimonials TP53 treatment Trial Patient USA videos-How Videos-Immuno Videos-Patients Videos-Surgery Videos-Trials whipple

Shared Information improves and Galvanises our Outcomes
What do you think about this video ? can you recommend a video? We welcome your comments?

By Steve|2024-10-11T16:13:32+10:00August 18th, 2018|Categories: Clinical Trials, Z-Legacy|Tags: Videos-Trials|0 Comments

Share this Story

FacebookXLinkedInWhatsAppEmail

About the Author: Steve

Founder & CEO at Cholangiocarcinoma Foundation Australia | Late-Stage, Stage 4 CCA Survivor | Passionate Road Cyclist | Personal page for details https://steveholmes.net.au/

Related Posts

Orphan Drug for Intrahepatic Bile Duct Cancer
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Evaluating the New Cholangiocarcinoma Vaccine Trial: A Patient-Centric Analysis”
Fixing Broken IDH1 in Cholangiocarcinoma: How Inhibitors Are Changing the Fight
IDH1-Mutated Cholangiocarcinoma: Understanding PARP Inhibitors and Clinical Trials
0 0 votes
Article Rating
Subscribe
Login
Notify of
guest

guest

0 Comments
Inline Feedbacks
View all comments
See All

Need Help Now?

Connect with Steve
+61 415 153 522
steve@cholangio.org

Connect with Claire
+61 431 180 783
claire@cholangio.org

Registered Charity Logo

Connect With Us

Patient-led. Built by survivors. Powered by action.

Cholangiocarcinoma Foundation Australia is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC).
Cholangiocarcinoma Foundation Australia has Deductible Gift Recipient (DGR) status with the Australian Tax Office.
Donations over $2 or more are tax-deductible.
ABN: 93665038102

Privacy Policy

© 2025 | All Rights Reserved | Cholangiocarcinoma Foundation Australia

Page load link
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply
Go to Top